Predict your next investment

Intrommune Therapeutics company logo
HEALTHCARE | Biotechnology
intrommune.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series B | Alive

Total Raised

$220K

Last Raised

$70K | 19 days ago

About Intrommune Therapeutics

Intrommune Therapeutics is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a therapeutic approach for the treatment of peanut and other food allergies. Intrommune’s mission is to develop safe and effective options for food allergy sufferers so they and their loved ones can live their lives without fear.

Intrommune Therapeutics Headquarter Location

20 W 125th St.

New York, New York, 10027,

United States

646-770-2533

Latest Intrommune Therapeutics News

Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit

Jul 23, 2021

Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit Scientific Data Outlines the Role of the Oral Mucosa in the Delivery of Peanut Allergy Immunotherapy NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) — Intrommune Therapeutics , a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is participating in the Next Generation Food Allergy Drug Summit. This annual event takes place July 20-22, 2021. William Reisacher, MD and Abhit Singh, MD are participating in the event for Intrommune. William Reisacher, MD, Professor of Otolaryngology and the Director of Allergy Services within the Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine/New York-Presbyterian Hospital, presented the following talk at the conference, “ Food 101: Why the Oral Cavity is the Best Classroom for Educating the Immune System .” Dr. Reisacher is also the inventor of oral mucosal immunotherapy (OMIT) and is a Senior Scientific Advisor to Intrommune Therapeutics. “We consider oral mucosal immunotherapy a super-strategy for the management of food allergies,” said Dr. Reisacher. “A toothpaste-based modality delivers allergens to the majority of the oral cavity surface area without the risk of significant ingestion of peanut protein. This optimizes both safety and efficacy, expanding on the successful peanut desensitization proven to occur when liquid peanut protein is repeatedly placed under the tongue, and provides more options for younger children.” Abhit Singh, MD, VP, Medical Affairs, Intrommune, presented a talk entitled, “ Highlighting the Regulatory Pathway & Timelines: Working Towards an IND .” Dr. Singh worked on Intrommune’s successful 2020 INT-301 IND submission to the FDA. INT301 is a first-in-class formulation designed to desensitize an individual with peanut allergy using a toothpaste delivery system, ideally protecting them in the event of accidental peanut exposure. “We are very excited about the currently enrolling phase 1B trial of INT301, and we hope to escalate our development program based on results of this study,” said Dr. Singh. “The successful development of INT301 will demonstrate that food allergy immunotherapy can be accurately and effectively dispensed in order to ensure comprehensive patient-safety.” Intrommune is actively enrolling patients in its phase1B clinical trial. More information about this trial can be found here: https://www.circuitclinical.com/trial-details/circuit-wny/138. About Peanut and Other Food Allergies Food allergies affect more than 220 million people, including approximately 32 million people in the U.S. Management of food allergies currently focuses on avoidance of exposure to triggering foods, though often such foods, including peanuts, are common ingredients in food products and therefore difficult to avoid. Many people with peanut allergy are accidentally exposed and experience potentially life-threatening reactions, including anaphylaxis, each year. Unfortunately, food allergy remains an area of tremendous unmet medical need. About Oral Mucosal Immunotherapy™ Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization. Success with allergy immunotherapy hinges on consistent exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT promises advantages over other approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and support of reliable, long-term adherence. About Intrommune Therapeutics Intrommune , dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly, disease-modifying solution for the greater than 220 million people, including 32 million people in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product, INT301, has entered phase 1 clinical trials and is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. For more information on Intrommune Therapeutics, please visit  http://www.intrommune.com Contact: Cautionary Statement Regarding Forward Looking Statements This release may contain “forward-looking statements.” Forward-looking statements are identified by certain words or phrases such as “may,” “will,” “aim,” “will likely result,” “believe,” “expect,” “will continue,” “anticipate,” “estimate,” “intend,” “plan,” “contemplate,” “seek to,” “future,” “objective,” “goal,” “project,” “should,” “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the company. The company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release. This release does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction. Continue Reading

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Intrommune Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intrommune Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Intrommune Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intrommune Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.